# Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

> **NCT06908733** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer (Stage III)

## Interventions

- **DRUG:** 3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.

## Key facts

- **NCT ID:** NCT06908733
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908733, "Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06908733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*